Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$9.77 +0.4%	$12.37	$4.88 ▼ $19.58	$211.98M	N/A	48,896 shs	77,987 shs
ADVM Adverum Biotechnologies	$2.97 +1.4%	$2.54	$1.78 ▼ $8.56	$62.32M	0.77	94,924 shs	128,001 shs
SGMT Sagimet Biosciences	$7.11 -3.3%	$8.67	$1.73 ▼ $11.41	$218.10M	3.37	745,858 shs	479,109 shs
SOPH SOPHiA GENETICS	$3.61 +4.9%	$3.31	$2.58 ▼ $4.92	$243.96M	1	91,854 shs	47,138 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	+0.41%	-9.37%	-31.34%	-6.95%	+976,999,900.00%
ADVM Adverum Biotechnologies	+1.37%	+3.85%	+10.00%	+34.39%	-58.69%
SGMT Sagimet Biosciences	-3.27%	-7.30%	-25.86%	+106.09%	+130.84%
SOPH SOPHiA GENETICS	+4.94%	+4.03%	0.00%	+26.67%	+4.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	3.9166 of 5 stars	3.4	3.0	0.0	4.8	2.4	0.8	0.0
SGMT Sagimet Biosciences	3.2234 of 5 stars	3.5	4.0	0.0	0.0	2.7	3.3	0.0
SOPH SOPHiA GENETICS	2.9553 of 5 stars	3.5	5.0	0.0	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$32.80	235.72% Upside
ADVM Adverum Biotechnologies	2.75	Moderate Buy	$19.75	564.98% Upside
SGMT Sagimet Biosciences	3.00	Buy	$25.67	260.99% Upside
SOPH SOPHiA GENETICS	3.00	Buy	$8.00	121.61% Upside

Current Analyst Ratings Breakdown

Latest ADVM, SGMT, SOPH, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $19.00
8/13/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00
8/11/2025	SGMT Sagimet Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
8/7/2025	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$29.00
7/24/2025	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/30/2025	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$6.31 per share	N/A
ADVM Adverum Biotechnologies	$1M	62.31	N/A	N/A	($0.96) per share	-3.09
SGMT Sagimet Biosciences	$2M	109.03	N/A	N/A	$4.24 per share	1.68
SOPH SOPHiA GENETICS	$69.69M	3.50	N/A	N/A	$1.13 per share	3.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	-$130.93M	-$7.85	N/A	N/A	N/A	N/A	-297.29%	-101.40%	11/3/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.83	N/A	N/A	N/A	N/A	-39.88%	-38.40%	N/A
SOPH SOPHiA GENETICS	-$62.49M	-$0.44	N/A	N/A	N/A	-40.99%	-30.69%	-17.39%	11/4/2025 (Estimated)

Latest ADVM, SGMT, SOPH, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AARD Aardvark Therapeutics	-$0.52	-$0.66	-$0.14	-$0.66	N/A	N/A
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.52	-$0.32	+$0.20	-$0.32	N/A	N/A
8/12/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	-$2.34	-$0.10	-$2.34	N/A	N/A
8/5/2025	Q2 2025	SOPH SOPHiA GENETICS	-$0.25	$0.33	+$0.58	$0.33	$17.49 million	$18.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	14.04	14.04
ADVM Adverum Biotechnologies	N/A	1.54	1.54
SGMT Sagimet Biosciences	N/A	17.55	17.55
SOPH SOPHiA GENETICS	0.62	3.39	3.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ADVM Adverum Biotechnologies	48.17%
SGMT Sagimet Biosciences	87.86%
SOPH SOPHiA GENETICS	31.59%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
ADVM Adverum Biotechnologies	6.00%
SGMT Sagimet Biosciences	14.70%
SOPH SOPHiA GENETICS	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
ADVM Adverum Biotechnologies	190	20.98 million	19.73 million	Optionable
SGMT Sagimet Biosciences	8	30.67 million	26.17 million	Optionable
SOPH SOPHiA GENETICS	520	67.58 million	64.28 million	Not Optionable

ADVM, SGMT, SOPH, and AARD Headlines

Recent News About These Companies

SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 48.6% in July

August 19, 2025 | marketbeat.com

SOPHiA GENETICS SA: Positive Earnings Call Highlights

August 14, 2025 | theglobeandmail.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Holdings Increased by Federated Hermes Inc.

August 9, 2025 | marketbeat.com

SOPHiA GENETICS Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

August 7, 2025 | finance.yahoo.com

Sophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

August 7, 2025 | finance.yahoo.com

SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlook

August 6, 2025 | msn.com

SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

SOPHiA GENETICS Reports Financial Results for Mid-2025

August 5, 2025 | tipranks.com

SOPHiA GENETICS Reports Second Quarter 2025 Results

August 5, 2025 | prnewswire.com

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

August 5, 2025 | prnewswire.com

Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 123.8%

August 5, 2025 | marketbeat.com

SOPHiA GENETICS (SOPH) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025

July 22, 2025 | prnewswire.com

Turning Proof Into Power: Bioz Partners With SOPHiA GENETICS to Enhance Scientific Transparency via Custom Integration

July 15, 2025 | pharmiweb.comP

Sophia Genetics launches podcast to decode data- and AI-driven medical innovation

June 27, 2025 | fiercepharma.comF

An end to an era: Supreme Court won't review IVF mixup ruling

June 26, 2025 | israelnationalnews.comI

Enough hype about AI in health—let’s talk about results

June 12, 2025 | fastcompany.comF

M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care

June 3, 2025 | zawya.comZ

M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care

June 3, 2025 | msn.com

M42, partners launch liquid biopsy testing in UAE

June 3, 2025 | tradearabia.comT

The Multimodal Imperative: How AI-Driven Technology is Driving Impactful Changes

June 2, 2025 | fiercepharma.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, SGMT, SOPH, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$9.77 +0.04 (+0.41%)

As of 08/22/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Adverum Biotechnologies NASDAQ:ADVM

$2.97 +0.04 (+1.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.96 -0.01 (-0.20%)

As of 08/22/2025 07:56 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Sagimet Biosciences NASDAQ:SGMT

$7.11 -0.24 (-3.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.19 +0.08 (+1.14%)

As of 08/22/2025 07:57 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

SOPHiA GENETICS NASDAQ:SOPH

$3.61 +0.17 (+4.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.60 -0.01 (-0.42%)

As of 08/22/2025 07:18 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time